Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced EGFR-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. Methods: We conducted a multicenter,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Cancer
Главные авторы: Wei, Yu-Feng, Huang, Wen-Tsung, Liu, Tu-Chen, Shieh, Jiunn-Min, Chian, Chih-Feng, Wu, Ming-Fang, Chang, Chih-Cheng, Lin, Ching-Hsiung, Ko, Jen-Chung, Lin, Chia-Mo, Hsia, Te-Chun
Формат: Artigo
Язык:Inglês
Опубликовано: Ivyspring International Publisher 2019
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692623/
https://ncbi.nlm.nih.gov/pubmed/31417660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.30507
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы